Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Simcere Pharmaceutical Group Limited
  6. Summary
    2096   HK0000658531

SIMCERE PHARMACEUTICAL GROUP LIMITED

(2096)
  Report
Delayed Hong Kong Stock Exchange  -  03:08 2022-12-09 am EST
9.500 HKD   +1.17%
12/01Simcere Pharmaceutical Group Completes Database Lock in Ischemic Stroke Treatment Study
MT
12/01Simcere Pharmaceutical Group Limited Announces A Multi-Center, Randomized, Double-Blind, Parallel and Placebo-Controlled Phase III Clinical Study
CI
11/16Idorsia, Simcere Pharmaceutical Strike Licensing Deal for Insomnia Drug Daridorexant in China
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Quotes 5-day view   Delayed Quote. Delayed Hong Kong Stock Exchange
12/05/2022 12/06/2022 12/07/2022 12/08/2022 12/09/2022 Date
10.02(c) 9.34(c) 9.32(c) 9.39(c) 9.5(c) Last
27 151 216 9 856 100 11 194 000 8 371 000 13 665 000 Volume
+5.25% -6.79% -0.21% +0.75% +1.17% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 908 M - -
Net income 2022 126 M - -
Net Debt 2022 378 M - -
P/E ratio 2022 25,6x
Yield 2022 1,22%
Sales 2023 1 085 M - -
Net income 2023 177 M - -
Net Debt 2023 426 M - -
P/E ratio 2023 18,4x
Yield 2023 1,53%
Capitalization 3 246 M 3 246 M -
EV / Sales 2022 3,99x
EV / Sales 2023 3,39x
Nbr of Employees 6 542
Free-Float 30,8%
More Financials
Company
Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces innovative drugs, such as Endostar used for oncology. The Company is also involved... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Ratings of Simcere Pharmaceutical Group Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about SIMCERE PHARMACEUTICAL GROUP LIMITED
12/01Simcere Pharmaceutical Group Completes Database Lock in Ischemic Stroke Treatment Study
MT
12/01Simcere Pharmaceutical Group Limited Announces A Multi-Center, Randomized, Double-Blind..
CI
11/16Idorsia, Simcere Pharmaceutical Strike Licensing Deal for Insomnia Drug Daridorexant in..
MT
11/15Simcere Pharmaceutical Obtains License to Develop, Market Idorsia's Insomnia Drug in Gr..
MT
11/09Simcere Pharmaceutical Group Limited Announces Executive Changes
CI
11/06Simcere Pharmaceutical Group Issues More Than 13 Milion New Shares
MT
10/26US FDA Approves Simcere Pharmaceutical's New Drug Application for Monoclonal Antibody
MT
10/26Simcere Pharmaceutical Group Limited Announces Approval of Investigational New Drug App..
CI
09/30Simcere Posts Drop In H1 Profit
MT
09/29Almirall Signs Exclusive Licensing Deal with Simcere for Autoimmune Drug Candidate
MT
09/28Simcere and Almirall Enter into a Licensing Agreement for IL-2 mu-Fc
PR
09/28Simcere Pharmaceutical Group Limited and Almirall, S.A. Enters into Licensing Agreement..
CI
09/28Simcere Grants Spain's Almirall Selling Rights for Autoimmune Drug Outside China
MT
09/05UBS Adjusts Simcere Pharmaceutical's Price Target to HK$13 From HK$12.50, Keeps at Buy
MT
09/05Simcere Pharmaceutical Announces Fin : 27% Year-Over-Year Revenue Growth, with Innovative ..
PR
More news
News in other languages on SIMCERE PHARMACEUTICAL GROUP LIMITED
12/05Idorsia: Swissmedic donne son feu vert pour le somnifère Quviviq
12/01Simcere Pharmaceutical Group Limited annonce une étude clinique de phase III multicentr..
11/16Bourse Zurich: les indices en recul après la chute du missile en Pologne
11/16Bourse Zurich: en baisse après la chute du missile en Pologne
11/16Bourse Zurich: en baisse après la chute de missiles en Pologne
More news
Analyst Recommendations on SIMCERE PHARMACEUTICAL GROUP LIMITED
More recommendations
ETFs positioned on SIMCERE PHARMACEUTICAL GROUP LIMITEDETFs and Trackers with Trackinsight
ETF WeightVar. 5daysRatingGeography
Loncar China BioPharma ETF - Distributing - USD2.33%1.63%China
KraneShares Emerging Market Healthcare Inde...0.3%0.51%NC
Vanguard FTSE Emerging Markets ETF - USD0.02%0.22%China
Vanguard FTSE Global All Cap ex Canada Inde...0%-1.23%World
More ETFs positioned on SIMCERE PHARMACEUTICAL GROUP LIMITED
Chart SIMCERE PHARMACEUTICAL GROUP LIMITED
Duration : Period :
Simcere Pharmaceutical Group Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SIMCERE PHARMACEUTICAL GROUP LIMITED
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 8,49 CNY
Average target price 11,01 CNY
Spread / Average Target 29,8%
EPS Revisions
Managers and Directors
Jin Sheng Ren Chairman & Co-Chief Executive Officer
Ren Hong Tang Chairman & Co-Chief Executive Officer
Yu Shan Wan CFO, Joint Secretary & Executive Director
Pin Wang Chief Scientific Officer
Mookerjee Bijoyesh Chief Medical Officer